Histide ^Hubs

Histide is a biotech intellectual property platform company pioneering a new class of non-mutagenic extracellular therapeutic agents called Cell Recoding Molecules (CRMs). This innovative platform builds on Histide's expertise in the mechanisms underlying the cell's microenvironmental sensing and signal transduction processes. The CRMs promote and stimulate the cell's natural capacities to redirect its own fate by integrating accurate extracellular signals. This is at the heart of Histide's groundbreaking approach of addressing diseases called Recoding Therapeutics that goes beyond traditional cell, gene or RNA based therapies. Histide has a technological breakthrough with vast indication spectra of pharmaceuticals, medical devices and medical cosmetics. Histide mission: Establish Cell Recoding Molecules (CRMs) as new class of therapeutic solutions. Their vision: To unlock the potential of Recoding Therapeutics by establishing an ecosystem of teams and partners, all committed to providing enhanced therapeutic solutions across diverse areas and routes of administration, for diseases that are untreatable or undruggable today.